Healthcare diagnostics startup Neuranics has successfully raised $700,000 in seed funding in a round led by Inflection Point Ventures (IPV).
This funding will fuel the company’s mission to innovate blood diagnostics, with a focus on advancing technology and completing clinical validations.
Neuranics aims to transform diagnostic practices with its breakthrough point-of-care blood analyzer, designed to deliver complete blood count (CBC) results within 10 minutes using just a finger-prick sample. This compact and efficient device is specifically tailored for primary care and emergency settings, offering unparalleled convenience and efficiency.
The traditional process of obtaining CBC results involves significant time and logistical challenges. Neuranics’ device eliminates delays associated with transporting and processing blood samples, ensuring physicians can access real-time data while consulting patients. This innovation not only streamlines decision-making but also improves patient outcomes by enabling timely diagnoses and treatments.
The device is particularly impactful for conditions like sepsis, severe anemia, and thrombocytopenia, where rapid intervention is critical. Additionally, it helps reduce the unnecessary use of antibiotics and other treatments, leading to cost savings and improved healthcare quality.
Founded in 2021 by Praveen Kumar and Ashutosh Patra, Neuranics addresses crucial gaps in diagnostic accessibility. Praveen, an IIT Delhi alumnus, brings extensive expertise in healthcare technology and has contributed to initiatives like Corona Kavach and Aarogya Setu. Ashutosh, a graduate of the SiB (formerly Stanford India Biodesign) program at AIIMS, leads product innovation with his background in optical sensing and mechanical engineering.
Together, they are redefining diagnostics with precision technologies such as microfluidics, machine vision, and AI-driven data analysis.
Dr. Megha Sharma, MD Pathologist and Chief Medical Evangelist at Neuranics, highlighted the device’s potential to make blood testing more accessible and patient-friendly. “By leveraging a simple finger-prick capillary sample, we’ve eliminated the need for venipuncture, making diagnostics less invasive and more efficient,” she stated.
This technology has significant implications for resource-limited settings, such as primary healthcare centers and emergency setups, enabling immediate, actionable insights.
Neuranics operates within a booming diagnostics industry. The global market for CBC testing is projected to reach $50 billion with a CAGR of 8–10%. With its focus on next-generation diagnostic technologies, Neuranics is poised to become a leader in the industry.
Mitesh Shah, Co-founder of IPV, emphasized the transformative potential of Neuranics’ solutions. “Their point-of-care blood analyzer simplifies CBC testing and enhances patient care, especially in critical scenarios. IPV is excited to support Neuranics as they redefine diagnostic practices.”
Praveen Kumar expressed the company’s commitment to elevating healthcare standards: “Our goal is to bring fast, accurate diagnostics closer to the patient without compromising on quality. By integrating AI and innovative technologies, we aim to establish India as a global leader in diagnostic advancements.”
With its cutting-edge innovations and strategic funding, Neuranics is well-positioned to lead a revolution in healthcare diagnostics, empowering clinicians and improving patient outcomes worldwide
